Welcome to the e-CCO Library!

DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Cohen1, H. Chang2, J.R. Jason Rogers1, S. Garg1, D. Lawrence3, F. Fasihuddin1, T. Lissoos4, A. Atreja5

Created: Thursday, 30 January 2020, 10:12 AM
DOP19: Incidence and initial disease presentation of inflammatory bowel diseases in Denmark: findings from a Copenhagen IBD Inception Cohort Study (IBD Prognosis Study)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Attauabi, M.(1,2)*;Madsen, G.R.(2,3);Wewer, A.V.(2,4);Bendtsen, F.(2,3);Jakobsen, C.(2,4);Dorn-Rasmussen, M.(2,4);Malham, M.(2,4);Theede, K.(2,3);Bjerrum, J.T.(1);Boysen, T.(2,3);Seidelin, J.B.(1);Burisch, J.(2,3);
Created: Friday, 14 July 2023, 10:43 AM
DOP19: Myeloid and lymphoid cell abnormalities persist in the intestinal mucosa of patients who recover from COVID-19 infection
Year: 2022
Source: ECCO'22
Authors: Meringer, H.(1);Tokuyama, M.(1);Tankelevich, M.(1);Martinez-Delgado, G.(1);Jha, D.(1); Livanos, A.E.(1);Canales-Herrerias, P.(1);Cossarini, F.(2);Mehandru , S.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP19: Spermidine treatment ameliorates experimental colitis in vivo
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Niechcial*1, E. Katkeviciute1, L. Hering1, M. Wawrzyniak1, M. Schwarzfischer1, K. Bäbler1, K. Attrot1, M. Scharl1,2, M. R. Spalinger1

Created: Friday, 22 February 2019, 9:41 AM
DOP19: Urinary metabolome in newly diagnosed treatment-naïve Crohn’s Disease patients: Results from the IBDomics study
Year: 2021
Source: ECCO'21 Virtual
Authors: Aldars-García, L.(1);Gil-Redondo, R.(2);Embade, N.(2);Riestra, S.(3);Rivero, M.(4);Gutiérrez, A.(5);Rodríguez, I.(6);Fernández, L.(7);Ceballos, D.(8);Benítez, J.M.(9);Aguas, M.(10);Bastón-Rey, I.(11);Algaba, A.(12);Casanova, M.J.(1);Lorente, R.(13);Ber, Y.(14);Royo, V.(15);Esteve, M.(16);Millet, O.(2);Gisbert, J.P.(1);Chaparro, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R.C.A. Lalisang1, G. Adriaans2, M. de Jong3, A. van der Meulen-de Jong4, M. Romberg-Camps5, N. Mahmmod6, T. Markus-de Kwaadsteniet7, G. Dijkstra8, J. Haans2, C. Stamm9, R. Vanwersch10, D. Jonkers11, R.J. Almeida12,13, M.J. Pierik2, MyIBDcoach Study Group

Created: Thursday, 30 January 2020, 10:12 AM
DOP20: Drugs that modulate histone acetylation disrupt TGF-β-signalling and reduce collagen I expression in models of stricturing Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Lewis*1, A. Nijhuis1, G. Berti1, C. Felice2, R. Jeffrey1, S. Iqbal1, A. B. Pomeranc1, S. Aldelemi1, S. Mehta1, E. Giannoulatou3, R. Feakins4, A. Armuzzi2, J. O. Lindsay5, A. Silver1

Created: Friday, 22 February 2019, 9:41 AM
DOP20: Functional viral neutralisation responses after SARS-CoV-2 infection in Inflammatory Bowel Disease patients receiving infusion therapies: Report from the ICARUS-IBD Consortium
Year: 2022
Source: ECCO'22
Authors: Wellens, J.(1,2);Edmans, M.(3);Obolski, U.(4,5);Marlow, L.(1);Brann, S.(1);Dunachie, S.(3,6,7);Eyre, D.(8,9);Helmus, D.(10);Barnes, E.(1,3);Colombel, J.F.(10);Wong, S.Y.(10);Klenerman, P.(1,3);Lindsay, J.O.(11,12);Thompson, C.P.(13);Satsangi, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP20: Genetic of vitamin D as predictor of response to adalimumab in Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Cusato, J.(1);Ribaldone, D.G.(1);Bertani, L.(2);Antonucci, M.(1);Tomasello, C.(3);Caviglia, G.P.(1);Dibetto, S.(1);Mangia, M.(1);Astegiano, M.(4);D'Avolio, A.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP20: The impact of early life antibiotics on the occurrence of paediatric inflammatory bowel disease - a nationwide study from 1995 – 2018
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jawad, A.(1);Jansson, S.(1,2);Malham, M.(1,2)*;Wewer, V.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Høivik1, M. Lördal2, J. Burisch3, E. Langholz4, T. Knudsen5, M. Voutilainen6, B. Moum1, K. Anisdahl1, B. Saebo7, P. Haiko8, C. Malmgren9, M. Coskun10, H.O. Melberg11

Created: Thursday, 30 January 2020, 10:12 AM
DOP21: Disease activity patterns of paediatric Inflammatory Bowel Disease – A Danish nationwide cohort study 1996-2018
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wewer, M.D.(1,2,3)*;Jansson, S.(3,4,5);Malham, M.(3,4,6);Burisch, J.(1,3);Wewer, V.(3,4,7);
Created: Friday, 14 July 2023, 10:43 AM
DOP21: Potential mechanisms linking biological therapies on SARS-CoV-2 susceptibility in Inflammatory Bowel Disease patients
Year: 2022
Source: ECCO'22
Authors: Pisani, L.F.(1);Mola, S.(2,3);Crespi, G.(2,3);Caprioli, F.(4,5);Pastorelli, L.(6,7);Annunziata, M.L.(1);Manfredi, M.(3,8);Porta, C.(2,3);
Created: Friday, 11 February 2022, 3:52 PM
DOP21: Role of P2X7 in intestinal fibrosis and inflammasome activation: Relevance in Crohn´s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Lis-López, L.(1);Bauset, C.(1);Ortiz-Masia, D.(1);Gisbert-Ferrándiz, L.(1);Coll, S.(1);Calatayud, S.(1);Barrachina, M.D.(1);Cosín-Roger, J.(2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP22 Certification of integral care IBD Units: Evaluation of a certification program (CUE)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Barreiro-de Acosta1, A. Gutierrez2, Y. Zabana3, B. Beltran4, X. Calvet5, M. Chaparro6, E. Domènech7, M. Esteve3, J. Panés8, J.P. Gisbert6, P. Nos4, on behalf of GETECCU

Created: Thursday, 30 January 2020, 10:12 AM
DOP22: Antibiotic Use as a Risk Factor for Inflammatory Bowel Disease Across the Ages: A Population-Based Cohort Study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Faye, A.(1)*;Allin, K.(2);Iversen, A.(3);Agrawal, M.(4);Faith, J.(5);Colombel, J.F.(5);Jess, T.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP22: Clinical, biochemical and endoscopic disease activity of Inflammatory Bowel Diseases are not associated with the severity or long-term outcomes of COVID-19 – A Danish prospective population-based cohort study
Year: 2022
Source: ECCO'22
Authors: Attauabi, M.(1,2,3);Dahlerup, J.F.(4);Poulsen, A.(5);Hansen, M.R.(6);Vester-Andersen, M.K.(7);Eraslan, S.(2);Prahm, A.P.(5);Pedersen, N.(8);Larsen, L.(9);Jess, T.(9,10);Neumann, A.(11);Haderslev, K.V.(12);Molazahi, A.(13);Lødrup, A.B.(14);Glerup, H.(15);Oppfeldt, A.M.(16);Jensen, M.D.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3); Danish COVID-IBD Study Group
Created: Friday, 11 February 2022, 3:52 PM
DOP22: Integrative -omic analysis reveals microbiota mediated molecular mechanisms influencing host mucosal gene expression in Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Sudhakar, P.(1);Andrighetti, T.(2);Verstockt, S.(1);Caenepeel, C.(1,3);Ferrante, M.(1,3);Sabino, J.(1,3);Verstockt., B.(1,3);Vermeire, S.(1,3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP22: UC-related and segment-specific properties of patient-derived colonic organoids
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Suzuki*1, H. Shimizu1, M. Kawai1, J. Takahashi1, S. Anzai1, A. Kawamoto1, S. Nagata1, Y. Hiraguri1, S. Yui1, K. Tsuchiya1, T. Nakamura1, K. Ohtsuka1, K. Ohtsuka1, R. Okamoto1, M. Watanabe1

Created: Friday, 22 February 2019, 9:41 AM
DOP23 Endoscopic evaluation at 1 month after ileocolic resection for Crohn’s disease predicts postoperative recurrence and is safe
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Z. Guo, Y. Zhu, L. Cao, Y. Li, Z. Wang, W. Zhu

Created: Thursday, 30 January 2020, 10:12 AM